Kiora Pharmaceuticals Inc... (KPRX)
3.18
-0.23 (-6.74%)
At close: Jan 14, 2025, 3:59 PM
3.25
2.20%
After-hours Jan 14, 2025, 06:18 PM EST
undefined% (undefined)
| Bid | 3.25 |
| Market Cap | 9.54M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.05 |
| PE Ratio (ttm) | 3.03 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.37 |
| Volume | 44,022 |
| Avg. Volume (20D) | 41,614 |
| Open | 3.46 |
| Previous Close | 3.41 |
| Day's Range | 3.10 - 3.46 |
| 52-Week Range | 3.00 - 8.98 |
| Beta | undefined |
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2015
Employees 12
Stock Exchange NASDAQ
Ticker Symbol KPRX
Website https://www.kiorapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 214.47% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Kiora Pharmaceuticals Inc. is scheduled to release its earnings on Mar 24, 2025,
before market opens.
Analysts project revenue of $750.00K, reflecting a n/a YoY growth and earnings per share of -0.7, making a -143.75% decrease YoY.
Analysts project revenue of $750.00K, reflecting a n/a YoY growth and earnings per share of -0.7, making a -143.75% decrease YoY.
9 months ago ·
Source
+14.41%
Kiora Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
11 months ago ·
Source
+53.92%
Kiora Pharmaceuticals shares are trading higher after the company announced a private placement of up to roughly $45 million.
